Investor Presentaiton
Clinical use case: COPD
Age 60
Indications Prior biologics therapeutic for re-current exacerbation
of moderate obstructive lung disease.
Sex
Baseline
TV
VH
Structural CT
XV LVAS
0.69L
60.8%
Summary.
•
.
•
SOB for further investigation.
At baseline CT was unremarkable. Placed on biologics for history
of exacerbation.
Following Tx, there are functional improvements in regional
ventilation indices (reduced VH and VDP). Notably, appearance of
improved. ventilation, specifically in the dependent areas of the
right and left lungs.
Corresponding with patient reported improvement in symptoms.
Clinical Observations
.
Improved symptoms demonstrated a clinical correlation with
improvements in regional ventilation function. Continued therapy
with novel biologics.
Functional assessment of regional ventilation assists in tracking
response to therapy and management.
5 Months Post-Tx
4DMedical Limited (ASX:4DX) Investor Presentation | September 2022
Structural CT
XV LVAS
TV
0.7L
VH
VDP
18.1%
VDP
4DMedical™
47.0% 13.4%
16View entire presentation